AOXIN Q & M DENTAL GRP LIMITED (1D4) Fair Value & Analysis
Healthcare · SG · Market cap 278M SGD
Fair value as of: Aug 13, 2026
From 26 valuation models · updated 4 days ago
Share price −4.3% over the past month.
Below-average quality, and screening another 85% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (0.0425 SGD). The favourable scenario is already priced in.
- Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range 0.0300 SGD – 0.3150 SGD · fair‑value band 0.0340 SGD – 0.0425 SGD · the 0.2250 SGD price screens above the 0.0340 SGD fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
AOXIN Q & M DENTAL GRP LIMITED (1D4) currently trades at 0.2250 SGD, while our model-based Fair Value estimate is 0.0340 SGD, implying the stock looks roughly 84.9% overvalued today. The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, AOXIN Q & M DENTAL GRP LIMITED generated revenue of 176M SGD at a net margin of 4.0%. Revenue declined 8.9% year over year. It earns a return on equity of 2.3%. Fundamentals as of Aug 13, 2026
Our scenario range runs from 0.0340 SGD (bear case) to 0.0425 SGD (bull case); at 0.2250 SGD, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 31% below its 52-week high, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at -85%, 1D4 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (0.2600 SGD) versus Dividend Discount (0.0300 SGD). Highest evidence: Growth DCF (80).
Notify me when 1D4 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 42 · Market factors (momentum, volatility) 58
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Aoxin Q & M Dental Group Limited, an investment holding company, provides private dental healthcare services in the People's Republic of China and Singapore. It operates through three segments: Primary Healthcare; Distribution of Dental Equipment and Supplies; and Laboratory Services.
Full company description
Aoxin Q & M Dental Group Limited, an investment holding company, provides private dental healthcare services in the People's Republic of China and Singapore. It operates through three segments: Primary Healthcare; Distribution of Dental Equipment and Supplies; and Laboratory Services. It offers private dental services, such as stomatology and general dentistry, endodontics, orthodontics, periodontics, prosthodontics, dental implantology, oral and maxillofacial surgery, aesthetic dentistry, and paedodontics; and operates dental centers comprising dental polyclinics and dental hospitals in Liaoning Province. The company also distributes and sells dental equipment and supplies, such as dental chairs, ultrasound scanners, dental instruments, and materials and consumables to dental hospitals, clinics, distributors, and laboratories. In addition, it provides laboratory services, which includes the manufacturing of porcelain crown, bridges, and dentures; and leases medical equipment. Further, the company offers technical and investment consultancy services; and develops dental inlay technology, as well as involved in trading of medical and dental instruments and supplies. Aoxin Q & M Dental Group Limited was founded in 1997 and is based in Singapore.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
AOXIN Q & M DENTAL GRP LIMITED reported revenue of 171M SGD in FY2025 versus 160M SGD in FY2021, a compound +1.7%/yr. Reported net income was 7.0M SGD in FY2025.
1D4 screens 85% overvalued. Compare with HCA Healthcare, Inc →
Peer Group
Medical Care Facilities · 267 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $414.59 | $547.67 | +32% |
| Fresenius SE FRE | €46.82 | €32.15 | -31% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.67 SGD | 1.44 SGD | -46% |
| Tenet Healthcare Corporation THC | $266.79 | $330.25 | +24% |
| Rede D'Or São Luiz S.A RDOR3 | R$33.97 | R$47.31 | +39% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,565 | ₹2,955 | -65% |
| Aier Eye Hospital Group 300015 | ¥8.87 | ¥7.67 | -14% |
| Max Healthcare Institute Limited MAXHEALTH | ₹1,008 | ₹284.87 | -72% |
| Bangkok Dusit Medical Services Public Company BDMS | 19.70 THB | 18.57 THB | -6% |
Compare AOXIN Q & M DENTAL GRP LIMITED with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is AOXIN Q & M DENTAL GRP LIMITED (1D4) overvalued or undervalued?
What is the fair value of 1D4?
What is the quality score of 1D4?
What is the revenue of AOXIN Q & M DENTAL GRP LIMITED (1D4)?
What is the net profit margin of 1D4?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track AOXIN Q & M DENTAL GRP LIMITED and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.